Posted on

Toppoint Holdings Inc. Announces Anticipated Reincorporation from Nevada to Delaware

NORTH WALES, PA, Sept. 14, 2026 (GLOBE NEWSWIRE) — Toppoint Holdings Inc. (“Toppoint” or the “Company”) (NYSE American: TOPP), a truckload services and solutions provider focused on the recycling export supply chain, today announced that it expects to reincorporate from the State of Nevada to the State of Delaware (the “Reincorporation”) pursuant to a plan of conversion (the “Plan of Conversion”). The Plan of Conversion is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on August 10, 2026, as supplemented by the Company’s definitive additional materials filed on August 24, 2026 (collectively, the “Proxy Statement”).

By sf-admin
Posted on

Mission Aviation Fellowship and LAMP aviation partnership supports lasting relationships in remote First Nations communities

Ahead of Canada’s National Day for Truth and Reconciliation, two aviation ministries highlight an approach built on invitation, long-term commitment, and relationships that extend far beyond the flight. 

Ahead of Canada’s National Day for Truth and Reconciliation, two aviation ministries highlight an approach built on invitation, long-term commitment, and relationships that extend far beyond the flight.

By sf-admin
Posted on

Lupus Nephritis Market on a Growth Trajectory at a CAGR of 7% During the Forecast Period (2026–2036), as Innovative Therapies Gain Momentum | DelveInsight

The lupus nephritis market is poised for significant growth over the coming years, driven by increasing disease awareness, improved diagnosis, and the expanding adoption of targeted therapies. The treatment landscape is evolving beyond conventional broad-spectrum immunosuppressants, with approved therapies such as belimumab, voclosporin, and obinutuzumab expanding treatment options for patients with active disease. At the same time, a robust pipeline of therapies such as Anifrolumab (SAPHNELO; AstraZeneca), Ianalumab (VAY736; Novartis/MorphoSys), Cenerimod (Idorsia Pharmaceuticals/Viatris), Rapcabtagene autoleucel (YTB323; Novartis), and others is expected to further transform disease management. 

The lupus nephritis market is poised for significant growth over the coming years, driven by increasing disease awareness, improved diagnosis, and the expanding adoption of targeted therapies. The treatment landscape is evolving beyond conventional broad-spectrum immunosuppressants, with approved therapies such as belimumab, voclosporin, and obinutuzumab expanding treatment options for patients with active disease. At the same time, a robust pipeline of therapies such as Anifrolumab (SAPHNELO; AstraZeneca), Ianalumab (VAY736; Novartis/MorphoSys), Cenerimod (Idorsia Pharmaceuticals/Viatris), Rapcabtagene autoleucel (YTB323; Novartis), and others is expected to further transform disease management.

By sf-admin